Novel cardiac MRI mapping techniques such as T1, T2 and ECV parametric mapping have been proven to detect early cardiotoxicity among patients taking chemotherapeutic drugs. We aimed to determine whether these parameters could predict the development of early onset cardiac dysfunction in HER 2 positive breast cancer patients who were on anthracyclines and trastuzumab. We demonstrated statistically and clinically significant drop in left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) at four months post chemotherapy. The change in the mapping values were not statistically significant, however there was a trend towards an increase in the ECV.
This abstract and the presentation materials are available to members only; a login is required.